KRAS and neoplasm: KRAS is a frequent mutation in NSCLC and is thought to be an “oncogenic driver”, partially explaining the controverse tumor cell reactivity, as LA can inhibit phosphatidylinositol 3‐kinase (PI3K) activated by a KRAS mutation.[13, 51]